Compare JD.Com Inc (JD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs BIO-TECHNE Corp — how do they compare? JD.Com Inc trades at $31.93 (market cap $45.40B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: JD.Com Inc is far larger — about 4× BIO-TECHNE Corp's market cap, and JD.Com Inc pays the higher dividend (2.99%). Which is the better fit depends on your goals.
| JD | TECH | |
|---|---|---|
Market Cap | $45.40B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $36.17 | $72.29 |
52-Week Low | $25.19 | $43.31 |
Enterprise Value | $31.45B | $11.32B |
Dividend Yield | 2.99% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $32.97, up 0.49% with bullish technical signals and strong institutional support. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $0.74 beating expectations by 30%. Revenue grew to $1.31 trillion in 2025, though net income margin compressed to 1.05%. Analysts maintain a strong buy consensus with $39.50 price target, representing 20% upside potential.
JD offers compelling value with attractive valuation multiples (P/S 0.25, P/E 24.03) and robust cash flow generation. Key risks include regulatory scrutiny of the Ceconomy acquisition and margin pressure from competitive e-commerce markets. The upcoming Q2 2026 earnings on August 13, 2026 will be critical for confirming growth trajectory.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
